Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAVrh.10hAPOE2
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Lexeo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : LX1001-01 (AAVrh.10hAPOE2) is an AAV-based investigational gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimer’s disease.
Brand Name : LX1001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : AAVrh.10hAPOE2
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Lexeo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ALN-APP
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration is focused on using [F-18]MK-6240 as a biomarker in neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Alnylam’s therapeutic ALN-APP, for the treatment of neurodegenerat...
Brand Name : ALN-APP
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 01, 2022
Lead Product(s) : ALN-APP
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?